

1 **Recent advances in technologies for vitamin A**
2 **protection in foods**

3

4 S. M. Loveday s.loveday@massey.ac.nz

5 H. Singh* h.singh@massey.ac.nz

6

7 Riddet Institute

8 Massey University

9 Private Bag 11 222

10 Palmerston North

11 NEW ZEALAND

12

13 * Corresponding author.

14 Tel.: +64 6 350 4401

15 Fax: +64 6 350 5655

16 **Abstract**

17 Vitamin A deficiency affects many children in the developing world,
18 and is preventable via food or pharmaceutical supplementation. The
19 main technical barrier to the fortification of food with vitamin A is its
20 susceptibility to oxidation and isomerization, which result in loss of
21 nutritional efficacy. This review discusses recent technological
22 avenues for stabilizing vitamin A in foods.

23 **Key Words**

24 vitamin A, retinoids, encapsulation, nutrition, nutraceutical, food
25 fortification, oxidation, isomerization, nanotechnology

26 **Introduction**

27 'Vitamin A' refers to a group of polyunsaturated hydrocarbons with
28 important nutritional roles in humans. The main compounds in this
29 group are the retinoids, which are chemical derivatives of retinol (Fig.
30 1), and provitamin A carotenoids, which are partially converted to
31 retinoids *in vivo*.

32 Adequate intake of vitamin A is vital to childhood development
33 because of its role in vision and ocular health, immune system
34 development, and neurological function. Vitamin A deficiency is a
35 major cause of death and disease in the developing world, especially
36 among mothers and infants.. Supplementation with large,
37 pharmaceutically administered doses of vitamin A can substantially
38 reduce the incidence and severity of some infectious diseases
39 (Villamor & Fawzi, 2005).

40 Fortification of foods is another strategy for combating vitamin A
41 deficiency, but fortification is not straightforward, for several reasons.
42 Firstly, as vitamin A is accumulated in the adipose tissue and high
43 levels are acutely toxic, the fortification of processed foods must be
44 regulated to avoid excessive vitamin A intake (Dary & Mora, 2002).
45 Secondly, vitamin A is poorly dispersible in aqueous systems such as
46 beverages and high moisture foods. Finally, vitamin A is highly labile
47 under ambient conditions, a problem that affects both food and
48 pharmaceutical supplementation routes. Large losses of vitamin A
49 activity can occur during processing, transportation and storage of
50 fortified foods (Dary & Mora, 2002). Adding vitamin A above the
51 intended fortification level to compensate for losses is undesirable
52 because of the potential for overdosing.

53 Technologies that enhance the stability of vitamin A in foods are
54 required for ensuring the safety and efficacy of the vitamin A
55 fortification of foods. This paper briefly discusses the factors affecting
56 vitamin A stability and then discusses the present state of the art in
57 vitamin A delivery technologies.

58 **Chemical instability of vitamin A**

59 The conjugated double bond system of retinoids (Fig. 1) and
60 carotenoids presents an electron-dense region that is attractive to
61 electron-deficient species, especially radicals. Retinoid degradation
62 displays characteristics that are typical of radical reactions – catalysis
63 by light, transition metals and free-radical-producing substances, and
64 inhibition by free-radical-quenching chemicals. Principles developed

65 in the study of polyunsaturated lipid reactions are relevant to retinoid
66 chemistry because of the common polyene chain (see Frankel,
67 (2005). The oxidation pathways for retinoids have been discussed in
68 a number of reviews, e.g. El-Agamey *et al.* (2004).

69 The double bonds in the polyene chain of retinoids can undergo
70 *cis-trans* isomerization, especially at positions 9, 11 and 13. *All-trans*
71 retinoids are predominant in food but minor amounts of other isomers
72 may also be present (Brinkmann, Dehne, Oei, Tiebach, & Baltes,
73 1995). *All-trans* retinol has maximal vitamin A activity, but
74 isomerization during the processing and storage of food (Ball, 1998)
75 results in partial loss of activity (Table 1). Several reaction schemes
76 for geometric isomerization have been proposed, e.g. Rozanowska
77 *et al.* (2005), but mechanistic understanding of isomerization
78 reactions is limited. Heat-induced isomerization of retinoids produces
79 mainly 13-*cis* isomers in milk (Panfili, Manzi, & Pizzoferrato, 1998).

80 Oxygen accelerates photo-catalysed degradation of retinoids under
81 some circumstances, but degradation in the presence of oxygen is
82 relatively slow without a catalyst such as light or chemically
83 generated free radicals (Failloux, Bonnet, Perrier, & Baron, 2004).

84 Degradation of vitamin A in foods is accelerated by exposure to light,
85 especially ultraviolet light at wavelengths below 415 nm (Garcia-
86 Fuentes, Torres, & Alonso, 2003). Retinoids are degraded faster
87 under ultraviolet-A light (UV-A, 315–400 nm) than under ultraviolet-B
88 light (UV-B, 280–315 nm) (Failloux *et al.*, 2004).

89 **Technologies for stabilizing retinoids**

90 The degradation of retinoids in aqueous solution is rapid (Semenova,
91 Cooper, Wilson, & Converse, 2002), and the solubility of retinoids in
92 aqueous solvents is poor because of their low polarity. Dispersibility
93 and stability can be improved by incorporating retinoids into colloidal
94 carrier particles. Carriers include single and double emulsions,
95 liposomes, solid lipid nanoparticles and polymeric micro- or
96 nanoparticles. Complexing retinoids with molecular carriers, such as
97 cyclodextrins and proteins, can also improve their stability.

98 Many of these technologies have been developed for cosmetic or
99 pharmaceutical applications and their performance in food systems is
100 poorly characterized. For example, the degradation of stabilized
101 retinoids is often evaluated in model cosmetic emulsions or gels.

102 The efficiency with which an active agent (AA) is incorporated into a
103 carrier matrix is expressed as a percentage, referred to as the
104 entrapment efficiency:

$$105 \quad \text{entrapment efficiency} = \frac{\text{total AA} - \text{unentrapped AA}}{\text{total AA}} \times 100$$

106 The capacity of an encapsulation system to carry an AA, or 'loading
107 capacity', is expressed as the percentage by weight of the 'capsule'
108 phase (entrapped AA + matrix) that comprises AA:

$$109 \quad \text{loading capacity} = \frac{\text{entrapped AA}}{\text{entrapped AA} + \text{matrix}} \times 100$$

110 **1. Emulsion systems**

111 Retinoids can be incorporated into foods as emulsions using an oil-
112 based carrier. The choice of carrier material is important because the
113 oxidative stability of the incorporated retinoid is influenced by droplet
114 physical characteristics (e.g. solid/liquid state, interfacial layer
115 thickness) and chemical characteristics (e.g. degree of unsaturation,
116 fatty acid chain length, presence of natural antioxidants). The basic
117 principles of emulsion preparation and stabilization have recently
118 been reviewed (McClements, Decker, & Weiss, 2007) and are not
119 discussed here.

120 Surprisingly few applications of oil-in-water (O/W) emulsions to
121 encapsulate retinoids are detailed in the scientific literature. A model
122 cosmetic vehicle was developed in the work of Carlotti, Rossatto, and
123 Gallarate (2002), in which vitamin A palmitate was dissolved in octyl
124 octanoate and emulsified in water with Montanov 68 EC® (cetearyl
125 alcohol and cetearyl glucoside). Vitamin A palmitate degraded
126 slightly faster in an O/W emulsion than in bulk octyl octanoate, which
127 was attributed to localization of vitamin A palmitate at the oil–water
128 interface (Carlotti et al., 2002).

129 Several patents for the use of O/W emulsions to deliver fat-soluble
130 vitamins into foods or pharmaceuticals have been filed (Hähnlein,
131 Hanse, & Olesen, 1998; Yaghmur *et al.*, 2007).

132 Microemulsions are thermodynamically stable mixtures of water, oil
133 and one or more amphiphiles, which assemble spontaneously into

134 nanometre-scale droplets (Flanagan & Singh, 2006). Suitable food-
135 grade surfactants include ethoxylated mono- and diacylglycerides
136 and phospholipids. Ethanol may be required as a co-surfactant to
137 solubilize long chain triglycerides (Flanagan, Kortegaard, Pinder,
138 Rades, & Singh, 2006).

139 O/W microemulsions are an efficient vehicle for incorporating
140 hydrophobic nutrients into aqueous systems, e.g. lycopene (Garti,
141 Yaghmur, Aserin, Spornath, Elfakess, & Ezrahi, 2004) and β -
142 carotene (Szymula, 2004). On exposure to sunlight, lycopene
143 degrades more slowly in O/W microemulsions than in an organic
144 solvent (Garti et al., 2004). However, Szymula (2004) reported that β -
145 carotene degradation in sunlight was fastest in O/W microemulsions,
146 followed by water-in-oil (W/O) microemulsions and pure pentanol.
147 Szymula (2004) suggested that the high concentration of β -carotene
148 in oil droplets of the O/W microemulsion promoted degradation.
149 Similar results have been reported with retinol in liposomes
150 (Tesoriere, Darpa, Re, & Livrea, 1997).

151 A patent for the use of O/W or W/O microemulsions to deliver
152 nutraceutical ingredients in foods has been granted (Garti, Abraham,
153 Spornath, & Idit, 2007), and the technology is marketed by
154 NutraLease Ltd (<http://www.nutralease.com>).

155 A double emulsion comprises either oil droplets inside water droplets,
156 suspended in an oil-based continuous phase (oil-in-water-in-oil,
157 O/W/O), or water droplets inside oil droplets in an aqueous
158 continuous phase (water-in-oil-in-water, W/O/W).

159 Yoshida, Sekine, Matsuzaki, Yanaki, and Yamaguchi (1999) made
160 O/W/O emulsions in which the outer oil phase contained an
161 organophilic clay and a non-ionic surfactant. Retinol was
162 incorporated into different types of emulsions, and stability decreased
163 in the order O/W/O > W/O > O/W. Yoshida *et al.* (1999) attributed
164 the stabilizing effect of the O/W/O emulsion to the exclusion of
165 oxygen from the inner oil phase by a surrounding water layer. Retinol
166 in the outer continuous phase of the W/O emulsion was more stable
167 than retinol in the disperse phase of the O/W emulsion, which does
168 not seem to be consistent with this theory. Retinol stability was
169 thought to be inadvertently compromised by lipid peroxide impurities
170 in the surfactant and metallic impurities in the clay, and stability was
171 improved by both water-soluble and oil-soluble antioxidants (Yoshida
172 *et al.*, 1999).

173 **2. Solid lipid nanoparticles**

174 Solid lipid nanoparticles (SLNs) with diameter 50–1000 nm have
175 been used for the delivery of lipophilic drugs and cosmetics because
176 they are well tolerated by the body (Müller, Mäder, & Gohla, 2000).
177 The carrier particles are made from lipids that solidify at room
178 temperature to form a crystalline or amorphous undercooled matrix in
179 which the AA is incorporated. To prepare SLNs, the AA (in this case
180 retinol, retinoic acid or a retinol ester such as retinyl palmitate) is first
181 solubilized in melted lipid, forming a 'melt', and nanoparticles are
182 prepared from the melt in one of three ways (Müller *et al.*, 2000).

- 183 • Hot homogenization: the melt is dispersed in a hot aqueous
184 solution of surfactant, homogenized at high pressure and then
185 cooled to room temperature.
- 186 • Cold homogenization: the melt is cooled to room temperature and
187 ground to microparticles. These are dispersed in cold surfactant
188 solution and homogenized, which produces cavitation forces that
189 are sufficient to break microparticles into nanoparticles.
- 190 • Microemulsion technique: the melt is dispersed in hot surfactant
191 solution to generate a microemulsion, which is then added to a
192 cold aqueous medium, causing solid lipid particles to precipitate.

193 Patents have been granted for the manufacture of SLNs by hot or
194 cold homogenization (Lucks & Müller, 1996) and by the
195 microemulsion technique (Gasco, 2002). Retinoid-loaded SLNs have
196 been produced by hot homogenization (Carlotti, Sapino, Trotta,
197 Battaglia, Vione, & Pelizzetti, 2005; Jennings & Gohla, 2000; Lim, Lee,
198 & Kim, 2004) and the microemulsion technique (Carlotti *et al.*, 2005).

199 Three models of drug incorporation into the SLN matrix have been
200 proposed: a homogeneous matrix, the outer shell enriched with AA
201 and the inner core enriched with AA (Müller *et al.*, 2000). The three
202 models are illustrated and discussed in more detail by McClements
203 *et al.* (2007).

204 A number of parameters affect the internal and membrane structure
205 of SLNs, their stability against aggregation and the protection
206 imparted to an entrapped AA. Cortesi, Esposito, Luca, and Nastruzzi

207 (2002) investigated the effect of numerous processing parameters on
208 SLN size, recovery and morphology.

209 **Manufacture method**

210 Cold homogenization favours a homogeneous matrix. In hot
211 homogenization methods, a shell rich in AA is formed if the lipid
212 crystallizes before the AA. If the AA crystallizes at a lower
213 temperature than the matrix, an enriched core forms. *All-trans* retinol
214 melts at 62–64°C (Schwieter & Isler, 1971).

215 **Surfactant system**

216 Lim and Kim (2002) reported that the incorporation of *all-trans*
217 retinoic acid into tricaprln SLNs was improved at higher surfactant
218 levels (which also produced smaller particles). They took this to
219 indicate that retinoic acid was incorporated into the surfactant layer
220 rather than into the lipid matrix. At constant surfactant level and
221 composition, retinol stability improved with decreasing particle size
222 and increasing total surface area (Müller, Radtke, & Wissing, 2002),
223 in agreement with the findings of Lim and Kim (2002).

224 The stability of SLNs against aggregation is affected by the ionic
225 strength of the continuous phase and the charge density at the
226 lipid–water interface (Garcia-Fuentes et al., 2003; Lim & Kim, 2002).
227 A large zeta potential (positive or negative) helps to stabilize SLNs
228 against aggregation, but non-electrostatic effects such as steric
229 stabilization may also be important (Garcia-Fuentes et al., 2003).

230 Lim and Kim (2002) reported that the aggregation stability of SLNs
231 loaded with all-*trans* retinoic acid could be optimized by altering the
232 balance of surfactants. Stability was further improved by the inclusion
233 of distearoylphosphatidyl ethanolamine–N-poly(ethylene glycol)
234 (DSPE–PEG), a polymer with both steric- and electrostatic-stabilizing
235 effects. In freeze-dried SLNs, retention of all-*trans* retinoic acid was >
236 90% after 3 months of storage at 4°C (Lim et al., 2004).

237 **Lipid type**

238 The loading capacities of SLNs are limited by expulsion of the AA
239 from lipid matrices as they crystallize (Müller *et al.*, 2000). Jennings
240 and Gohla (2000) entrapped retinoids in a range of glycerides and
241 waxes. Retention of the AA within the lipid matrix was poor with the
242 waxes and tripalmitate, the lipids forming relatively pure crystals.

243 Mixed lipids form less perfect crystals, and the AA can be retained in
244 the space created by crystal imperfections (Müller *et al.*, 2000). This
245 type of SLN is sometimes termed a ‘nanostructured lipid carrier’
246 (NLC) or ‘oil-loaded SLN’. Three types of structures are formed on
247 cooling the lipid mixtures: imperfect crystals containing many
248 imperfections, amorphous undercooled lipid and liquid lipid droplets
249 in a solid lipid matrix (McClements et al., 2007).

250 Jores, Haberland, Wartewig, Mäder, and Mehnert (2005) found
251 evidence that solid lipids in mixed-lipid SLNs crystallized in a platelet
252 shape, expelling liquid lipid droplets to the surface. Liquid droplets
253 containing a lipophilic marker were poorly protected from the external
254 aqueous environment (Jores *et al.*, 2005). However, Garcia-Fuentes,

255 Alonso, and Torres (2005) produced tripalmitin SLNs with a short
256 chain triacylglycerol that appeared to form oily domains within SLNs.

257 In the work of Jennings and Gohla (2001), the stability of retinol in
258 glyceryl behenate SLNs was improved by adding a low melting
259 medium chain triglyceride. Jennings and Gohla (2001) also reported
260 that the stability of different retinoids in mixed-lipid SLNs followed the
261 order of polarity: retinyl palmitate > retinol > retinoic acid.

262 Hu, Jiang, Du, Yuan, Ye, and Zeng (2005) produced nanoparticles
263 from a mixture of stearic and oleic acids, and reported that increasing
264 oleic acid content produced smoother particles with decreased
265 crystallinity and increased drug loading capacity. Jennings and Gohla
266 (2001) reported that adding 5–10% liquid lipid to SLNs improved the
267 retinol loading capacity and stability, and postulated the existence of
268 liquid and solid lipid domains within particles.

269 Carlotti *et al.* (2005) and Sapino, Carlotti, Pelizzetti, Vione, Trotta,
270 and Battaglia (2005) tested the stability of retinyl palmitate in cetyl
271 palmitate, glyceryl behenate and palmitic acid SLNs during exposure
272 to UV light or prolonged storage. Stability was evaluated in model
273 cosmetic systems – an O/W emulsion (Carlotti *et al.*, 2005) and a
274 hydroxyethylcellulose gel (Sapino *et al.*, 2005). Retinyl palmitate in
275 SLNs degraded more slowly than free retinyl palmitate. SLNs made
276 with different lipids had similar light-scattering properties but the least
277 polar lipid, cetyl palmitate, best protected retinyl palmitate against UV
278 irradiation. This may have been due to improved retention of retinyl
279 palmitate in the lipid matrix.

280 Mixed-lipid nanoparticle carriers have apparently not been patented.

281 **3. Liposomes**

282 Liposomes can be made by adding buffer to powdered phospholipid
283 or a dried phospholipid film formed by rotary evaporation of an
284 organic solvent. The organic solvents used in film formation are not
285 acceptable in food.

286 Entrapment of retinoids in the lipid bilayers of multilamellar liposomes
287 has been shown to improve their stability in the presence of oxygen
288 (Lee, Yuk, Lee, Lee, Hwang, & Ludescher, 2002). Incorporation of
289 retinol into liposomes at a retinol:phospholipid ratio of 1:100 is up to
290 99% efficient, but liposomes offer little protection in acidic conditions
291 or at temperatures at or above ambient (Lee et al., 2002). The
292 process used to manufacture liposomes in this case used chloroform
293 and methanol (Lee *et al.*, 2002). Retinol shows greater affinity than
294 retinyl palmitate for entrapment into liposomes (Singh & Das, 1998).

295 Young and Gregoriadis (1996) reported that incorporating retinol into
296 liposomes accelerated photodegradation relative to free retinol in
297 methanol. Similarly, Tesoriere *et al.* (1997) found an increase in the
298 retinol degradation rate with increasing concentration of liposome-
299 encapsulated retinol. It was suggested that degradation reactions
300 involving two retinol molecules were accelerated by concentrating
301 retinol in liposomes (Young & Gregoriadis, 1996).

302 Liposome encapsulation can be combined with other mechanisms to
303 enhance stability. Loukas, Jayasekera, and Gregoriadis (1995)

304 reported that the rate of riboflavin degradation under UV light was
305 reduced up to 75% by incorporation into liposomes. Complexing
306 riboflavin with γ -cyclodextrin slowed degradation by a further 80% at
307 the expense of an approximately 50% reduction in entrapment
308 efficiency (Loukas, Jayasekera, & Gregoriadis, 1995). McCormack
309 and Gregoriadis (1998) reported 19% efficient entrapment of a
310 retinol–hydroxypropyl β -cyclodextrin complex in liposomes but did
311 not examine the effect on retinol oxidation or isomerization.

312 Liposomes can be stabilized against aggregation by coating with
313 chitosan and incorporating them into microparticles (Ruan, Ng, &
314 Feng, 2004). They can also encapsulate other particles, e.g.
315 polymeric vesicles of palmitoyl glycol chitosan (McPhail, Tetley,
316 Dufes, & Uchegbu, 2000).

317 In a related technology, lipid-soluble compounds can be incorporated
318 into vesicles of a non-ionic surfactant (niosomes). Encapsulation of
319 β -carotene in niosomes comprising cholesterol and Tween or Span
320 surfactants slows its degradation in sunlight and hydrogen peroxide
321 solution, relative to free β -carotene (Palozza, Muzzalupo, Trombino,
322 Valdannini, & Picci, 2006). Manconi, Valenti, Sinico, Lai, Loy, and
323 Fadda (2003) tested a range of non-ionic surfactants for their ability
324 to stabilize all-*trans* retinoic acid in niosomes irradiated with UV light,
325 and found that two of the formulations improved stability relative to
326 retinoic acid in methanol. However these authors used chloroform to
327 manufacture niosomes, and for that reason the process is not
328 suitable for food applications.

329 **4. Cochleates**

330 Cochleates are micro- or nanoparticles consisting of phospholipid
331 bilayers stacked as sheets and rolled into a spiral configuration with
332 aqueous solutions of multivalent cations between each sheet
333 (BioDelivery Sciences International, 2008). This is illustrated
334 schematically in Fig. 2. Cochleates are prepared by slowly
335 introducing polyvalent cations into anionic liposome suspensions,
336 causing the liposomes to fuse.

337 In the ‘trapping’ method, calcium chloride is added dropwise to a
338 liposome suspension, and cochleate formation is indicated by an
339 immediate increase in turbidity (Evans & Zasadzinski, 2003). Small
340 unilamellar liposomes prepared by film hydration give more uniform
341 cigar-shaped cochleates than multilamellar liposomes from powdered
342 phospholipids (Zarif, 2005).

343 For the ‘hydrogel process’, liposomes are mixed with a polymer such
344 as dextran and injected into a solution of a second, non-miscible
345 polymer, e.g. PEG. Calcium is added to the water-in-water emulsion
346 and diffuses slowly from the PEG continuous phase into the
347 dispersed dextran–liposome phase, producing nanocochleates
348 (Santangelo *et al.*, 2000). Sub-micrometre cochleates can be
349 produced with this method whereas the trapping method gives larger
350 cochleates.

351 Cochleates are most frequently made with dioleoyl phosphatidyl
352 serine and calcium chloride – natural ingredients that are acceptable
353 in food systems (Evans & Zasadzinski, 2003; Walker, Kennedy, &

354 Zasadzinski, 1997). Calcium can be replaced with zinc ions (Zarif,
355 Jin, Segarra, & Mannino, 2005) or organic cations (Jin, 2004).

356 Substances in the interior of liposomes are encapsulated in the
357 cochleate when the cation is added. Santangelo *et al.* (2000)
358 prepared cochleates from liposomes containing amphotericin B, a
359 hydrophobic antimycotic drug. They used the hydrogel method,
360 which gave cochleates with mean diameter 407 nm. The cochleate-
361 encapsulated drug was highly effective against fungal infections in
362 mice (Santangelo *et al.*, 2000). It appears that encapsulating
363 retinoids in cochleates had not been attempted at the time of writing.

364 Cochleates can be used as intermediates for encapsulating small
365 liposomes or colloidal particles, thus double-encapsulating labile
366 substances (Evans & Zasadzinski, 2003; Walker *et al.*, 1997).
367 Cations are chelated when EDTA is added to a suspension of
368 colloidal particles and cochleates, causing the cochleates to unroll
369 and close into vesicles around the particles. Walker *et al.* (1997)
370 attached colloidal particles to cochleate phospholipids with specific
371 ligand-receptor molecules, but the encapsulation efficiency was poor.

372 The company BioDelivery Sciences International Inc. has filed
373 several US and international patents related to the incorporation of
374 vitamin A in nanocochleates to enhance stability. Cochleate
375 manufacture with the hydrogel method is claimed (Mannino &
376 Krause-Elsmore, 2004), as is incorporation of liposomes into
377 cochleates (Krause-Elsmore & Mannino, 2005) and several other
378 applications (Zarif *et al.*, 2005).

379 **5. Cyclodextrin inclusion complexes**

380 Cyclodextrins (CDs) are rings of α -1,4 bonded glucose molecules
381 with a slightly hydrophobic interior that can entrap molecules less
382 polar than water (Szejtli, 1998). Natural, underivatized CDs contain
383 six, seven or eight glucose molecules and are referred to as α -, β -
384 and γ -CDs respectively. Methods for forming complexes between
385 CDs and nutritional or pharmaceutical AAs have been reviewed by
386 Szente (1996).

387 Retinoid-CD complexes have been prepared by mixing solutions at
388 room temperature in aqueous ethanol (Semenova *et al.*, 2002) or
389 methanol (Guo, Ren, Fang, & Liu, 1995). Another method is to form a
390 film of retinoid on the surface of a flask, add aqueous CD solution to
391 the flask and stir for several days (McCormack & Gregoriadis, 1998;
392 Munoz-Botella, Martin, Del Castillo, Lerner, & Menendez, 2002).

393 Inclusion of unstable or poorly water-soluble molecules in CDs can
394 improve their solubility in aqueous systems. For example, the
395 aqueous solubility of all-*trans* retinoic acid increases by more than
396 100 times after complexation with β -CD (Qi & Shieh, 2002) and more
397 than 10 000 times after complexation with hydroxypropyl β -CD (Lin,
398 Chean, Ng, Chan, & Ho, 2000). The solubility of the β -CD-retinoic
399 acid complex is better at neutral pH than acidic pH (Lin *et al.*, 2000;
400 Yap, Liu, Thenmozhiyal, & Ho, 2005). This may be because COO^-
401 groups of retinoic acid molecules, which are more ionized at neutral
402 pH, can interact with the hydroxyl groups of CDs (Lin *et al.*, 2000).

403 The solubility of β -CD complexes can be improved by organic salts.
404 Qi and Shieh (2002) reported a 26-fold increase in β -CD–retinoic
405 acid complex with the addition of 1.5% sodium acetate. Sodium
406 acetate also improves the solubility of hydrocortisone in β -CD, with
407 an optimum concentration of 2% (Loftsson, Matthiasson, & Masson,
408 2003). Some organic polymers enhance the solubilizing effect of
409 CDs, e.g. carboxymethylcellulose (Qi & Shieh, 2002) and poly(vinyl
410 pyrrolidone) (Loftsson & Brewster, 1996).

411 CDs have found widespread application in chromatographic methods
412 and as drug carriers (Szejtli, 1998). Complexation of retinoids with
413 CDs has been demonstrated by several groups (McCormack &
414 Gregoriadis, 1998; Munoz-Botella et al., 2002; Yap et al., 2005).
415 Semenova *et al.* (2002) reported good encapsulation and protection
416 of all-*trans* retinol with two cyclodextrin formulations, but did not show
417 sufficient data to verify this.

418 Association constants for several retinoid-cyclodextrin complexes are
419 shown in Table 2. Binding is most favourable at neutral pH (Lin *et al.*,
420 2000). Cyclodextrin binding studies have also been carried out on
421 several cis-retinoids (Munoz-Botella et al., 2002; Yap et al., 2005)
422 and carotenoids (Polyakov, Leshina, Konovalova, Hand, & Kispert,
423 2004)

424 Complexing retinoids with CDs inhibits photoisomerization (Munoz-
425 Botella *et al.*, 2002) and photodegradation (Yap *et al.*, 2005). The
426 retinoid polyene chain is held in the CD cavity (Yap *et al.*, 2005),
427 which dampens the torsion and rotation required for isomerization

428 (Munoz-Botella *et al.*, 2002). CD complexes of all-*trans* retinaldehyde
429 photoisomerize preferentially to the 13-*cis* form but retinoic acid-CD
430 complexes isomerize to a mixture of 9-, 11- and 13-*cis* isomers
431 (Munoz-Botella *et al.*, 2002).

432 The molar ratio of CD to retinoid molecule in the inclusion complex is
433 usually 1:1 or 2:1 (Guo *et al.*, 1995; Munoz-Botella *et al.*, 2002), but
434 ratios as high as 4.5:1 have been reported (McCormack &
435 Gregoriadis, 1998). The stoichiometry of the inclusion complex can
436 change as a function of CD concentration, e.g. hydroxypropyl β -CD
437 forms complexes with all-*trans* retinoic acid in a molar ratio of 1:1 at
438 low CD concentration and in a molar ratio of 2:1 at higher CD
439 concentration (Lin *et al.*, 2000).

440 CDs are already used in foods to encapsulate colours, flavours and
441 polyunsaturated fatty acids, and to prevent turbidity in drinks.

442 The stabilizing effect of CDs on vitamin A has been known for some
443 time, and was claimed in a 1955 US patent (Schlenk, Sand, &
444 Tillotson, 1955). A number of Japanese patents have claimed
445 methods for stabilizing vitamins with CD complexes, e.g. Takeshi and
446 Okihiko (1994). In 1994, a US patent for a method of enhancing
447 complexation between lipophilic food additives (including vitamin A)
448 and CDs using natural or synthetic hydrophilic polymers was granted
449 (Loftsson, 1994). Complexes of retinol or retinyl esters with γ -CDs
450 are described in a 1999 US patent (Moldenhauer, Regiert, &
451 Wimmer, 1999).

452 **6. Polymer encapsulation**

453 Polymers used for encapsulating retinoids in solid particles include
454 proteins, polysaccharides and synthetic polymers. The choice of
455 polymer in food systems is restricted by food regulations, and only
456 food-safe solvents may be used in particle manufacture.
457 Encapsulation of lipophilic drugs in polymer particles can be
458 improved by complexation with CDs (Duchene, Ponchel, &
459 Wouessidjewe, 1999).

460 Hwang, Oh, and Oh (2005) and Lee, Oh, Moon, and Bae (2001)
461 successfully entrapped retinol in 0.5–10 μm silica particles made
462 using a multiple emulsion technique. Encapsulation efficiencies of
463 7.4–30.9% (Hwang *et al.*, 2005) and 35.9–44.0% (Lee *et al.*, 2001)
464 were achieved. In a similar procedure, Ribeiro, Neufeld, Arnaud, and
465 Chaumeil (1999) produced chitosan-coated alginate microspheres,
466 with mean diameter 500–800 μm , containing soybean oil droplets
467 and an oil-soluble marker dye. The marker dye was released slowly
468 at pH 1.2 and faster at pH 7.5, and the speed of release depended
469 on the thickness of the coating (Ribeiro *et al.*, 1999).

470 Polymer particles can be prepared by coacervation, which is also
471 referred to as nanoprecipitation, drowning out or solvent
472 displacement. In this technique, the polymer and the AA are
473 dissolved in an organic solvent, which is emulsified in an aqueous
474 surfactant solution. The solvent is evaporated from the O/W emulsion
475 and the polymer precipitates, forming solid particles.

476 Biodegradable copolymers of lactic acid and glycolic acid (PLGA)
477 have been widely used in drug delivery applications, and at least two
478 research groups have encapsulated retinoids in copolymer
479 microparticles (Cirpanli, Unlu, Calis, & Hincal, 2005; Jeong et al.,
480 2003). Particles of 1–100 μm were prepared with the coacervation
481 technique, and an encapsulation efficiency of up to 74% was
482 reported (Cirpanli et al., 2005; Jeong et al., 2003). However, the
483 solvents commonly used to dissolve PLGA polymers are not
484 permitted in food systems.

485 Since the 1950s, vitamin A has been encapsulated in solid gelatin
486 beadlets for incorporation into animal feeds. In this process, an
487 emulsion containing antioxidants, starch, gelatin and sugars, is spray
488 congealed and the beadlet is cross linked by thermal or chemical
489 means. Other protein encapsulants include collagen and gliadin.

490 Gliadin is a hydrophobic wheat protein that is insoluble in water but
491 soluble in 70% ethanol. Hydrophobic AAs can be entrapped in gliadin
492 nanoparticles by coacervation. Gliadin particles of about 500 nm with
493 a payload of 76.4 μg of retinoic acid per milligram of protein were
494 prepared by Duclairoir, Irache, Nakache, Orecchioni, Chabenat, and
495 Popineau (1999). These workers demonstrated controlled release of
496 retinoic acid over 3 h, but did not examine degradation of the
497 entrapped retinoic acid. Preparation of gliadin-coated lipid particles
498 using a salting-out method has also been reported (Mauguet,
499 Legrand, Brujes, Carnelle, Larre, & Popineau, 2002).

500 Swatschek, Schatton, Müller, and Kreuter (2002) used microparticles
501 of marine sponge collagen (120–300 nm) as carriers for retinol
502 adsorbed on the surface. In a model cosmetic cream containing
503 retinol-loaded collagen particles, retention was over 50% after 8
504 weeks at 21°C.

505 It was recently reported that nanoparticle complexes can be formed
506 in mixtures of gum arabic and sodium caseinate, and that the particle
507 characteristics can be tailored by manipulating the ratio of caseinate
508 to gum arabic (Ye, Flanagan, & Singh, 2006). Such
509 protein–carbohydrate nanoparticle complexes may be suitable
510 vehicles for vitamin A encapsulation.

511 Encapsulation of lipophilic substances in polymer beads has been
512 the subject of several patents. Mandralis and Tuot (1997) patented a
513 process for encapsulating AAs in biopolymer particles by high
514 pressure gelation of a natural polymer encapsulant. Catron and
515 Mann (2000) produced beads loaded with hydrophobic AA by heat
516 setting or chemically cross linking emulsion droplets. Lim and Moss
517 (1983) devised a process in which alginate-containing emulsion
518 droplets are solidified by immersion in alcoholic solutions of
519 multivalent cations. A similar method using a mixture of cationic and
520 anionic polymers is the subject of a patent application (Cattaneo,
521 2005).

522 **7. Protein binding**

523 In living organisms, retinoids are non-covalently bound by proteins of
524 the 'lipid-binding protein' family, which transport fatty acids and other
525 small hydrophobic ligands in plants, animals and bacteria (De Wolf &
526 Brett, 2000). Retinol may also be bound to proteins in food matrices,
527 especially those containing lipid-binding whey proteins, e.g. β -
528 lactoglobulin and bovine serum albumin (BSA).

529 β -Lactoglobulin exists in bovine milk as a dimer at pH 6.5 with two
530 binding sites per dimer, and has a tertiary structure very similar to
531 those of retinol-binding proteins in the human body (Perez & Calvo,
532 1995). The fluorescence of retinol is enhanced by β -lactoglobulin,
533 because binding restricts the mobility of the retinol molecule, and
534 fluorescence enhancement can be used to quantify binding affinity
535 (Collini, D'Alfonso, Molinari, Ragona, Catalano, & Baldini, 2003).
536 Retinoic acid dissociates from the retinoic acid- β -lactoglobulin
537 complex below pH 7.0 because of conformational changes in the
538 protein, and will re-associate on neutralization (Zsila, Bikadi, &
539 Simonyi, 2002).

540 Chemical derivatization of β -lactoglobulin can alter its functional
541 properties, including retinoid binding. Methyl- or ethyl-alkylation of β -
542 lactoglobulin improves the binding of retinol, retinoic acid, retinyl
543 acetate and β -carotene (Dufour & Haertle, 1991). Hattori, Okada, and
544 Takahashi (2000) reported that conjugating carboxymethyl CD to β -
545 lactoglobulin improved the emulsifying activity and pH stability.

546 Antioxidant properties and retinol binding were not affected (Hattori
547 et al., 2000).

548 In the work of Shimoyamada, Yoshimura, Tomida, and Watanabe
549 (1996), retinoic acid or retinol complexed with β -lactoglobulin
550 degraded more slowly than the uncomplexed retinoids during 6 h of
551 UV irradiation. Hattori, Watabe, and Takahashi (1995) reported that
552 β -lactoglobulin protected retinol during irradiation and exposure to
553 high temperature or acidic pH. Retinol retention was > 60% after 5 h
554 at 60°C (compared with 30% without β -lactoglobulin); higher
555 temperatures denatured the protein and destroyed the protective
556 effect. More than 80% of the initial retinol was retained after 5 h at
557 37°C and pH 3–9 (Hattori et al., 1995).

558 BSA also binds retinoids, resulting in enhanced fluorescence. BSA
559 inhibits light-induced degradation of retinol to a similar extent to β -
560 lactoglobulin, but does not protect retinoic acid (Shimoyamada et al.,
561 1996).

562 Carotenes are bound to lipoproteins in some vegetables,
563 cyanobacteria, animals and crustaceans. The structure and the
564 biological function of carotenoproteins have been discussed in the
565 literature (Flower, 1996), and there is potential to use them as means
566 of encapsulating labile nutrients (De Wolf & Brett, 2000).

567 **8. Glassy matrix encapsulation**

568 Encapsulation of β -carotene in amorphous trehalose (a disaccharide)
569 has been shown to slow degradation during extended storage,

570 provided the trehalose can be prevented from absorbing moisture
571 and crystallizing (Elizalde, Herrera, & Buera, 2002). A process for
572 encapsulating vitamins or minerals in glassy fructo-oligosaccharides
573 has been patented (Leusner, Lakkis, van Lengerich, & Thomas,
574 2002).

575 **9. Antioxidants**

576 Some antioxidants improve the stability of retinoids during exposure
577 to light or oxygen. Butylated hydroxytoluene (BHT) is an oil-soluble
578 phenolic antioxidant that competes with radical propagation
579 reactions. Carlotti *et al.* (2002) reported that BHT slowed the
580 degradation of retinyl palmitate under UV irradiation in a sealed
581 container, but Failloux *et al.* (2004) found no effect in oxygenated
582 retinol solution exposed to UV-A light. Retinoid destruction in
583 oxygenated solutions kept in the dark was slowed by α -tocopherol
584 but not by β -carotene or ascorbic acid in the work of Ihara,
585 Hashizume, Hirase, and Suzue (1999).

586 Antioxidants work well as an adjunct to other encapsulation
587 techniques. For example, the retinol stability in O/W/O emulsions is
588 improved by both oil-soluble (BHT) and water-soluble (sodium
589 ascorbate) antioxidants (Yoshida *et al.*, 1999).

590 **Summary and conclusions**

591 Vitamin A supplementation via foods and/or pharmaceuticals has the
592 potential to prevent disease and ensure healthy childhood
593 development in developing countries. Technical barriers to delivering

594 vitamin A in foods include its poor dispersibility in aqueous systems
595 and its vulnerability to degradation during processing, transport and
596 storage. As the risk of overdosing precludes high dose fortification to
597 compensate for losses, there is a need for technologies that slow
598 vitamin A degradation.

599 Slowing the degradation of vitamin A relies on protecting it from
600 influences that accelerate degradation, particularly UV light, chemical
601 catalysts (especially metal contaminants and lipid hydroperoxides)
602 and oxygen. Much of the research into technologies for protecting
603 vitamin A does not examine the mechanistic rationale for an
604 improvement in stability, but instead takes a 'screening' approach.

605 Vitamin A supplementation via foods requires that the amount of
606 vitamin A present at the time of consumption is sufficiently high to be
607 therapeutic and sufficiently low to minimise the risk of overdosing.
608 Maintaining vitamin A activity within the bounds of safety and
609 effectiveness requires limiting the loss of activity through oxidation
610 and isomerization. It is therefore important to assess both the loading
611 capacity of an encapsulation system (which depends on entrapment
612 efficiency) and the stability of encapsulated vitamin A under
613 conditions relevant to food processing and storage.

614 Table 2 summarises the loading capacity, entrapment efficiency and
615 stability improvement of a range of vitamin A protection technologies
616 discussed here. It is evident from table 2 that the entrapment
617 efficiency of encapsulation systems is seldom measured. This is
618 important because a significant proportion of vitamin A mixed with an

619 encapsulant can remain free in solution or adsorbed on surfaces,
620 where it will be exposed to conditions that catalyse oxidation and/or
621 isomerisation. Without a knowledge of encapsulation efficiency it is
622 impossible to evaluate true loading capacity, and therefore difficult to
623 compare the effectiveness of different systems. It is not possible to
624 evaluate the commercial potential of diverse technologies based on
625 information in the academic literature because the costs of
626 ingredients are never disclosed in articles.

627 Also notable in Table 2 is a scarcity of technologies that use food-
628 safe manufacturing processes. This probably results from the fact
629 that much vitamin A stabilization research is oriented towards
630 pharmaceutical applications, in which doses are low, or cosmetic
631 products that are applied dermally and not consumed.

632 Emulsions can act as a vehicle for dispersing large amounts of
633 hydrophobic material in an aqueous system. The photostability of
634 labile nutrients is sometimes improved by emulsification, and synergy
635 between oil- and water-soluble antioxidants is enhanced in these
636 systems. Microemulsions and multiple emulsions have shown some
637 promise in stabilizing hydrophobic nutrients, and warrant further
638 investigation.

639 SLNs provide a physical barrier between retinoids and oxidation
640 catalysts, and their light-scattering properties (Müller et al., 2002)
641 reduce the intensity of light reaching the AAs entrapped in them.
642 SLNs made with anionic stabilizers tend to aggregate at low pH, but
643 non-ionic polymers can provide sufficient steric stabilization to

644 overcome this. Amphiphilic polymer stabilizers such as PEG
645 derivatives and copolymers of polyoxyethylene and polyoxypropylene
646 (trade names Pluronic, Poloxamer) provide effective steric
647 stabilization at low pH.

648 Stabilization in solid lipid particles requires efficient incorporation and
649 retention in the lipid matrix, which is best achieved with mixed lipids
650 that form impure crystals, undercooled melts or oil droplets within a
651 solid matrix. The lipid-soluble antioxidants butylated hydroxyanisole,
652 BHT, propyl gallate and α -tocopherol can further enhance the
653 stability of lipid-encapsulated retinoids.

654 Entrapment in liposomes protects vitamin A under some conditions,
655 but little protection is afforded at acidic pH and ambient or higher
656 temperature. Some authors have reported accelerated degradation
657 of vitamin A in liposomes, relative to free vitamin A. This has been
658 speculatively attributed to the high local concentration inside
659 liposomes, which presumably accelerates autoxidation.

660 Methods for preparing liposomes in the laboratory often use solvents
661 that are unacceptable for food systems, and published results may
662 be difficult to reproduce in food-safe systems. Liposomes can be
663 made more robust with a protective coating (Ruan *et al.*, 2004) or by
664 incorporation inside a multilayer encapsulation system (Evans &
665 Zasadzinski, 2003).

666 Lipid cochleates are very effective at protecting and delivering drugs,
667 but to date there have been no applications in foods, probably

668 because existing processes for making cochleates use toxic
669 solvents. Cochleates may be useful as intermediates in the
670 preparation of 'vesicles in vesicles' (Evans & Zasadzinski, 2003).

671 Retinoids may be more stable dispersed or dissolved in an aqueous
672 phase than in lipid droplets or particles, for two reasons: (1) oxygen
673 is less soluble in water than in lipids, and (2) lipid hydroperoxides are
674 absent in the aqueous phase. Stability would be compromised if
675 retinoids were brought into close contact with aqueous oxidation
676 catalysts such as transition metal ions. The aqueous solubility of
677 vitamin A is greatly improved by complexing with CDs.

678 Vitamin A has been incorporated into solid particles of proteins
679 (gelatin, collagen, gliadin), carbohydrates (alginate, chitosan) and
680 synthetic polymers (silicates, PLGA copolymers). Encapsulation
681 processes have been reported and, in some cases, patented, but the
682 stability of polymer-encapsulated vitamin A is not often evaluated in
683 the literature. Polymer particles range in size from hundreds of
684 nanometres to hundreds of micrometres, which may not be suitable
685 for liquid foods.

686 Carotenoids are often complexed with proteins in biological systems,
687 and vitamin A will form water-soluble complexes with certain
688 proteins. BSA and β -lactoglobulin offer some protection against
689 photo-oxidation, heating and acidic pH. Other plant or animal
690 proteins may also form soluble complexes with retinoids that
691 preserve vitamin A activity in food systems.

692 It is uncommon to find 'silver bullet' solutions to food preservation
693 problems; a combination of approaches such as the 'hurdle-
694 technology' concept (Leistner & Gorris, 1995) is more often
695 successful. Protecting vitamin A is just such a problem, because
696 retinoids and carotenoids must be stabilized against several chemical
697 and physical degradation catalysts, and protection is often achieved
698 at the expense of loading capacity. Synergistic protective effects are
699 seen when individual technologies are combined, such as
700 incorporating antioxidants into emulsions or SLNs, and encapsulating
701 CD complexes inside liposomes. In our opinion, the most promising
702 advances in vitamin A protection in foods will come from
703 consideration of the multifaceted nature of vitamin degradation and
704 the potential to combine technologies in ways that take advantage of
705 their individual strengths.

706 **References**

707

708 Ames, S. R., Swanson, W. J., & Harris, P. L. (1955). Biochemical
709 studies on vitamin A. XIV. Biopotencies of geometric isomers of
710 vitamin A acetate in the rat. *Journal of the American Chemical*
711 *Society*, 77(15), 4134-4136.

712 Ball, G. F. M. (1998). Vitamin A and the provitamin A carotenoids. In
713 G. F. M. Ball (Ed.), *Bioavailability and analysis of vitamins in food*
714 (pp. 115-162). London, UK: Chapman and Hall.

715 BioDelivery Sciences International. 2008. Bioral Technology.
716 <http://www.biodeliverysciences.com/technology/bioral.html>.
717 Accessed May 2008.

718 Brinkmann, E., Dehne, L., Oei, H. B., Tiebach, R., & Baltes, W.
719 (1995). Separation of geometrical retinol isomers in food samples by
720 using narrow-bore high-performance liquid-chromatography. *Journal*
721 *of Chromatography A*, 693(2), 271-279.

722 Carlotti, M. E., Rossatto, V., & Gallarate, M. (2002). Vitamin A and
723 vitamin A palmitate stability over time and under UVA and UVB
724 radiation. *International Journal of Pharmaceutics*, 240(1-2), 85-94.

725 Carlotti, M. E., Sapino, S., Trotta, M., Battaglia, L., Vione, D., &
726 Pelizzetti, E. (2005). Photostability and stability over time of retinyl
727 palmitate in an O/W emulsion and in SLN introduced in the emulsion.
728 *Journal of Dispersion Science and Technology*, 26(2), 125-138.

- 729 Catron, D. H., & Mann, O. J. (2000). Method and protecting heat- or
730 oxygen-labile compounds to preserve activity and bioavailability.
731 Kemin Industries Inc., US patent 6146671.
- 732 Cattaneo, M. V. (2005). Particles for the delivery of active agents.
733 IVREA Pharmaceuticals, US patent application US20050281886 A1.
- 734 Cirpanli, Y., Unlu, N., Calis, S., & Hincal, A. A. (2005). Formulation
735 and in-vitro characterization of retinoic acid loaded poly (lactic-co-
736 glycolic acid) microspheres. *Journal of Microencapsulation*, 22(8),
737 877-889.
- 738 Collini, M., D'Alfonso, L., Molinari, H., Ragona, L., Catalano, M., &
739 Baldini, G. (2003). Competitive binding of fatty acids and the
740 fluorescent probe 1-8-anilinonaphthalene sulfonate to bovine beta-
741 lactoglobulin. *Protein Science*, 12(8), 1596-1603.
- 742 Cortesi, R., Esposito, E., Luca, G., & Nastruzzi, C. (2002). Production
743 of lipospheres as carriers for bioactive compounds. *Biomaterials*,
744 23(11), 2283-2294.
- 745 Dary, O., & Mora, J. O. (2002). Food fortification to reduce vitamin A
746 deficiency: International Vitamin A Consultative Group
747 recommendations. *Journal of Nutrition*, 132(9), 2927S-2933S.
- 748 De Wolf, F., & Brett, G. (2000). Ligand-binding proteins: their
749 potential for application in systems for controlled delivery and uptake
750 of ligands. *Pharmacological Reviews*, 52(2), 207-236.

- 751 Duchene, D., Ponchel, G., & Wouessidjewe, D. (1999). Cyclodextrins
752 in targeting - application to nanoparticles. *Advanced Drug Delivery*
753 *Reviews*, 36(1), 29-40.
- 754 Duclairoir, C., Irache, J. M., Nakache, E., Orecchioni, A. M.,
755 Chabenat, C., & Popineau, Y. (1999). Gliadin nanoparticles:
756 formation, all-trans-retinoic acid entrapment and release, size
757 optimization. *Polymer International*, 48(4), 327-333.
- 758 Dufour, E., & Haertle, T. (1991). Binding of retinoids and beta-
759 carotene to beta-lactoglobulin. Influence of protein modifications.
760 *Biochimica et Biophysica Acta*, 1079(316-320).
- 761 El-Agamey, A., Lowe, G. M., McGarvey, D. J., Mortensen, A., Phillip,
762 D. M., Truscott, T. G., *et al.* (2004). Carotenoid radical chemistry and
763 antioxidant/pro-oxidant properties. *Archives of Biochemistry and*
764 *Biophysics*, 430(1), 37-48.
- 765 Elizalde, B. E., Herrera, M. L., & Buera, M. P. (2002). Retention of
766 beta-carotene encapsulated in a trehalose-based matrix as affected
767 by water content and sugar crystallization. *Journal of Food Science*,
768 67(8), 3039-3045.
- 769 Evans, C. C., & Zasadzinski, J. (2003). Encapsulating vesicles and
770 colloids from cochleate cylinders. *Langmuir*, 19(8), 3109-3113.
- 771 Failloux, N., Bonnet, I., Perrier, E., & Baron, M. H. (2004). Effects of
772 light, oxygen and concentration on vitamin A1. *Journal of Raman*
773 *Spectroscopy*, 35(2), 140-147.

- 774 Farrell, H. M., Jr., Jimenez-Flores, R., Bleck, G. T., Brown, E. M.,
775 Butler, J. E., Creamer, L. K., Hicks, C. L., Hollar, C. M., Ng-Kwai-
776 Hang, K. F., & Swaisgood, H. E. (2004). Nomenclature of the
777 Proteins of cows' milk - sixth revision. *Journal of Dairy Science*,
778 87(6), 1641-1674.
- 779 Flanagan, J., Kortegaard, K., Pinder, D. N., Rades, T., & Singh, H.
780 (2006). Solubilisation of soybean oil in microemulsions using various
781 surfactants. *Food Hydrocolloids*, 20(2-3), 253-260.
- 782 Flanagan, J., & Singh, H. (2006). Microemulsions: a potential delivery
783 system for bioactives in food. *Critical Reviews in Food Science and*
784 *Nutrition*, 46(3), 221-237.
- 785 Flower, D. R. (1996). The lipocalin protein family: structure and
786 function. *Biochemical Journal*, 318(Pt 1), 1-14.
- 787 Frankel, E. N. (2005). *Lipid oxidation* (2nd ed.). Bridgwater, UK: Oily
788 Press.
- 789 Garcia-Fuentes, M., Alonso, M. J., & Torres, D. (2005). Design and
790 characterization of a new drug nanocarrier made from solid-liquid
791 lipid mixtures. *Journal of Colloid and Interface Science*, 285(2), 590-
792 598.
- 793 Garcia-Fuentes, M., Torres, D., & Alonso, M. J. (2003). Design of
794 lipid nanoparticles for the oral delivery of hydrophilic
795 macromolecules. *Colloids and Surfaces B-Biointerfaces*, 27(2-3),
796 159-168.

- 797 Garti, N., Abraham, A., Spernath, A., & Idit, A. (2007). Nano-sized
798 self-assembled liquid dilutable vehicles. NutraLease Ltd., US patent
799 7182950.
- 800 Garti, N., Yaghmur, A., Aserin, A., Spernath, A., Elfakess, R., &
801 Ezrahi, S. (2004). Solubilization of active molecules in
802 microemulsions for improved environmental protection. *Colloids and*
803 *Surfaces A: Physicochemical and Engineering Aspects*, 230, 183-
804 190.
- 805 Gasco, M. (2002). Solid lipid microspheres having a narrow size
806 distribution and method for producing them. European patent EP
807 0526666 B2.
- 808 Guo, Q. X., Ren, T., Fang, Y. P., & Liu, Y. C. (1995). Binding of
809 vitamin A by beta-cyclodextrin and heptakis(2,6-o-dimethyl)-beta-
810 cyclodextrin. *Journal of Inclusion Phenomena and Molecular*
811 *Recognition in Chemistry*, 22(4), 251-256.
- 812 Hähnlein, W., Hanse, M. M., & Olesen, J. E. (1998). Stable
813 emulsions and dry powder from mixtures of fat-soluble vitamins, their
814 process of preparation and their use. BASF AG, European patent EP
815 0835613.
- 816 Hattori, M., Okada, Y., & Takahashi, K. (2000). Functional changes in
817 beta-lactoglobulin upon conjugation with carboxymethyl cyclodextrin.
818 *Journal of Agricultural and Food Chemistry*, 48(9), 3789-3794.
- 819 Hattori, M., Watabe, A., & Takahashi, K. (1995). Beta-lactoglobulin
820 protects beta-ionone related compounds from degradation by

- 821 heating, oxidation, and irradiation. *Bioscience Biotechnology and*
822 *Biochemistry*, 59(12), 2295-2297.
- 823 Hu, F. Q., Jiang, S. P., Du, Y. Z., Yuan, H., Ye, Y. Q., & Zeng, S.
824 (2005). Preparation and characterization of stearic acid
825 nanostructured lipid carriers by solvent diffusion method in an
826 aqueous system. *Colloids and Surfaces B: Biointerfaces*, 45(3-4),
827 167-173.
- 828 Hwang, Y. J., Oh, C., & Oh, S. G. (2005). Controlled release of
829 retinol from silica particles prepared in O/W/O emulsion: the effects
830 of surfactants and polymers. *Journal of Controlled Release*, 106(3),
831 339-349.
- 832 Ihara, H., Hashizume, N., Hirase, N., & Suzue, R. (1999).
833 Esterification makes retinol more labile to photolysis. *Journal of*
834 *Nutritional Science and Vitaminology*, 45(3), 353-358.
- 835 Jennings, V., & Gohla, S. (2000). Comparison of wax and glyceride
836 solid lipid nanoparticles (SLN(R)). *International Journal of*
837 *Pharmaceutics*, 196(2), 219-222.
- 838 Jennings, V., & Gohla, S. (2001). Encapsulation of retinoids in solid
839 lipid nanoparticles (SLN). *Journal of Microencapsulation*, 18(2), 149-
840 158.
- 841 Jeong, Y. I., Song, J. G., Kang, S. S., Ryu, H. H., Lee, Y. H., Choi,
842 C., *et al.* (2003). Preparation of poly(DL-lactide-co-glycolide)
843 microspheres encapsulating all-trans retinoic acid. *International*
844 *Journal of Pharmaceutics*, 259(1-2), 79-91.

- 845 Jin, T. (2004). Cochleates without metal cations as the bridging
846 agents. WIPO patent application WO 2004012709 A1.
- 847 Jores, K., Haberland, A., Wartewig, S., Mäder, K., & Mehnert, W.
848 (2005). Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by
849 spectrofluorometry and Raman spectroscopy. *Pharmaceutical*
850 *Research*, 22(11), 1887-1897.
- 851 Krause-Elsmore, S., & Mannino, R. (2005). Rigid liposomal cochleate
852 and methods of use and manufacture. Biodelivery Sciences
853 International Inc., WIPO patent WO 2005063213 A1.
- 854 Lee, M. H., Oh, S. G., Moon, S. K., & Bae, S. Y. (2001). Preparation
855 of silica particles encapsulating retinol using O/W/O multiple
856 emulsions. *Journal of Colloid and Interface Science*, 240(1), 83-89.
- 857 Lee, S. C., Yuk, H. G., Lee, D. H., Lee, K. E., Hwang, Y. I., &
858 Ludescher, R. D. (2002). Stabilization of retinol through incorporation
859 into Liposomes. *Journal of Biochemistry and Molecular Biology*,
860 35(4), 358-363.
- 861 Leistner, L., & Gorris, L. G. M. (1995). Food Preservation by Hurdle
862 Technology. *Trends in Food Science and Technology*, 6(2), 41-46.
- 863 Leusner, S. J., Lakkis, J., van Lengerich, B. H., & Thomas, J. (2002).
864 Oligosaccharide encapsulated mineral and vitamin ingredients.
865 General Mills, US patent 6468568.
- 866 Lim, F., & Moss, R. D. (1983). Vitamin encapsulation. Damon
867 Corporation, USA patent US 4389419.

- 868 Lim, S. J., & Kim, C. K. (2002). Formulation parameters determining
869 the physicochemical characteristics of solid lipid nanoparticles loaded
870 with all-trans retinoic acid. *International Journal of Pharmaceutics*,
871 243(1-2), 135-146.
- 872 Lim, S. J., Lee, M. K., & Kim, C. K. (2004). Altered chemical and
873 biological activities of all-trans retinoic acid incorporated in solid lipid
874 nanoparticle powders. *Journal of Controlled Release*, 100(1), 53-61.
- 875 Lin, H. S., Chean, C. S., Ng, Y. Y., Chan, S. Y., & Ho, P. C. (2000).
876 2-Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and
877 photostability of all-trans-retinoic acid. *Journal of Clinical Pharmacy*
878 *and Therapeutics*, 25(4), 265-269.
- 879 Loftsson, T. (1994). Cyclodextrin complexation. Cyclops h.f., US
880 patent 5472954.
- 881 Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications
882 of cyclodextrins.1. Drug solubilization and stabilization. *Journal of*
883 *Pharmaceutical Sciences*, 85(10), 1017-1025.
- 884 Loftsson, T., Matthiasson, K., & Masson, M. (2003). The effects of
885 organic salts on the cyclodextrin solubilization of drugs. *International*
886 *Journal of Pharmaceutics*, 262(1-2), 101-107.
- 887 Loukas, Y. L., Jayasekera, P., & Gregoriadis, G. (1995). Novel
888 liposome-based multicomponent systems for the protection of
889 photolabile agents. *International Journal of Pharmaceutics*, 117(1),
890 85-94.

- 891 Lucks, S., & Müller, R. H. (1996). Medication vehicles made of solid
892 lipid particles (solid lipid nanospheres - SLN). Medac GmbH,
893 European patent EP 0605497 B2.
- 894 Manconi, M., Valenti, D., Sinico, C., Lai, F., Loy, G., & Fadda, A. M.
895 (2003). Niosomes as carriers for tretinoin. II. Influence of vesicular
896 incorporation on tretinoin photostability. *International Journal of*
897 *Pharmaceutics*, 260(2), 261-272.
- 898 Mandralis, Z. I., & Tuot, J. (1997). Process for encapsulating a core
899 material with a polymer by high-pressure treatments. Nestle S.A.,
900 European patent EP 0750854 A2.
- 901 Mannino, R., & Krause-Elsmore, S. (2004). Cochleate preparations
902 of fragile nutrients. BioDelivery Sciences International Inc., WIPO
903 patent application WO 2004064805 A1.
- 904 Mauguet, M. C., Legrand, J., Brujes, L., Carnelle, G., Larre, C., &
905 Popineau, Y. (2002). Gliadin matrices for microencapsulation
906 processes by simple coacervation method. *Journal of*
907 *Microencapsulation*, 19(3), 377-384.
- 908 McClements, D. J., Decker, E. A., & Weiss, J. (2007). Emulsion-
909 based delivery systems for lipophilic bioactive components. *Journal*
910 *of Food Science*, 72(8), R109-R124.
- 911 McCormack, B., & Gregoriadis, G. (1998). Drugs-in-cyclodextrins-in-
912 liposomes: an approach to controlling the fate of water insoluble
913 drugs in vivo. *International Journal of Pharmaceutics*, 162(1-2), 59-
914 69.

- 915 McPhail, D., Tetley, L., Dufes, C., & Uchegbu, I. F. (2000).
916 Liposomes encapsulating polymeric chitosan based vesicles - a
917 vesicle in vesicle system for drug delivery. *International Journal of*
918 *Pharmaceutics*, 200(1), 73-86.
- 919 Moldenhauer, J. P., Regiert, M., & Wimmer, T. (1999). Complexes of
920 gamma-cyclodextrin and retinol or retinol derivatives, processes for
921 their preparation and use. Wacker-Chemie GmbH, US patent
922 5985296.
- 923 Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles
924 for controlled drug delivery - a review of the state of the art.
925 *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1),
926 161-177.
- 927 Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid
928 nanoparticles (SLN) and nanostructured lipid carriers (NLC) in
929 cosmetic and dermatological preparations. *Advanced Drug Delivery*
930 *Reviews*, 54, S131-S155.
- 931 Munoz-Botella, S., Martin, M. A., Del Castillo, B., Lerner, D. A., &
932 Menendez, J. C. (2002). Differentiating geometrical isomers of
933 retinoids and controlling their photo-isomerization by complexation
934 with cyclodextrins. *Analytica Chimica Acta*, 468(1), 161-170.
- 935 Palozza, P., Muzzalupo, R., Trombino, S., Valdannini, A., & Picci, N.
936 (2006). Solubilization and stabilization of beta-carotene in niosomes:
937 delivery to cultured cells. *Chemistry and Physics of Lipids*, 139(1),
938 32-42.

- 939 Panfili, G., Manzi, P., & Pizzoferrato, L. (1998). Influence of thermal
940 and other manufacturing stresses on retinol isomerization in milk and
941 dairy products. *Journal of Dairy Research*, 65(2), 253-260.
- 942 Perez, M. D., & Calvo, M. (1995). Interaction of beta-lactoglobulin
943 with retinol and fatty acids and its role as a possible biological
944 function for this protein: a review. *Journal of Dairy Science*, 78(5),
945 978-988.
- 946 Polyakov, N. E., Leshina, T. V., Konovalova, T. A., Hand, E. O., &
947 Kispert, L. D. (2004). Inclusion complexes of carotenoids with
948 cyclodextrins: 1HNMR, EPR, and optical studies. *Free Radical*
949 *Biology and Medicine*, 36(7), 872-880.
- 950 Qi, Z. H., & Shieh, W. J. (2002). Aqueous media for effective delivery
951 of tretinoin. *Journal of Inclusion Phenomena and Macrocyclic*
952 *Chemistry*, 44(1-4), 133-136.
- 953 Ribeiro, A. J., Neufeld, R. J., Arnaud, P., & Chaumeil, J. C. (1999).
954 Microencapsulation of lipophilic drugs in chitosan-coated alginate
955 microspheres. *International Journal of Pharmaceutics*, 187(1), 115-
956 123.
- 957 Rozanowska, M., Cantrell, A., Edge, R., Land, E. J., Sarna, T., &
958 Truscott, T. G. (2005). Pulse radiolysis study of the interaction of
959 retinoids with peroxy radicals. *Free Radical Biology and Medicine*,
960 39(10), 1399-1405.
- 961 Ruan, G., Ng, J. K., & Feng, S. S. (2004). Effects of polymer, organic
962 solvent and mixing strength on integrity of proteins and liposomes

- 963 encapsulated in polymeric microspheres fabricated by the double
964 emulsion process. *Journal of Microencapsulation*, 21(4), 399-412.
- 965 Santangelo, R., Paderu, P., Delmas, G., Chen, Z. W., Mannino, R.,
966 Zarif, L., *et al.* (2000). Efficacy of oral cochleate-amphotericin B in a
967 mouse model of systemic candidiasis. *Antimicrobial Agents and*
968 *Chemotherapy*, 44(9), 2356-2360.
- 969 Sapino, S., Carlotti, M. E., Pelizzetti, E., Vione, D., Trotta, M., &
970 Battaglia, L. (2005). Protective effect of SLNs encapsulation on the
971 photodegradation and thermal degradation of retinyl palmitate
972 introduced in hydroxyethylcellulose gel. *Journal of Drug Delivery*
973 *Science and Technology*, 15(2), 159-165.
- 974 Schlenk, H., Sand, D., & Tillotson, J. (1955). Stabilization of
975 materials. University of Minnesota, US patent 2827452.
- 976 Schwieter, U., & Isler, O. (1971). II. Chemistry. In O. Isler, G.
977 Gutmann & U. Solms (Eds.), *Carotenoids* (pp. 5-35). Basel, Stuttgart:
978 Birkhäuser-Verlag.
- 979 Semenova, E. M., Cooper, A., Wilson, C. G., & Converse, C. A.
980 (2002). Stabilization of all-trans-retinol by cyclodextrins: a
981 comparative study using HPLC and fluorescence spectroscopy.
982 *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 44(1-4),
983 155-158.
- 984 Shimoyamada, M., Yoshimura, H., Tomida, K., & Watanabe, K.
985 (1996). Stabilities of bovine beta-lactoglobulin/retinol or retinoic acid
986 complexes against tryptic hydrolysis, heating and light-induced

- 987 oxidation. *Lebensmittel-Wissenschaft und -Technologie*, 29(8), 763-
988 766.
- 989 Singh, A. K., & Das, J. (1998). Liposome encapsulated vitamin A
990 compounds exhibit greater stability and diminished toxicity.
991 *Biophysical Chemistry*, 73(1-2), 155-162.
- 992 Swatschek, D., Schatton, W., Müller, E. E. G., & Kreuter, J. (2002).
993 Microparticles derived from marine sponge collagen (SCMPs):
994 preparation, characterization and suitability for dermal delivery of all-
995 trans retinol. *European Journal of Pharmaceutics and*
996 *Biopharmaceutics*, 54(2), 125-133.
- 997 Szejtli, J. (1998). Introduction and general overview of cyclodextrin
998 chemistry. *Chemical Reviews*, 98(5), 1743-1753.
- 999 Szente, L. (1996). Preparation of cyclodextrin complexes. In J. Szejtli
1000 & T. Osa (Eds.), *Comprehensive supramolecular chemistry* (Vol. 3,
1001 pp. 243-252). New York, NY: Pergamon Press.
- 1002 Szymula, M. (2004). Atmospheric oxidation of beta-carotene in
1003 aqueous, pentanol, SDS microemulsion systems in the presence and
1004 absence of vitamin C. *Journal of Dispersion Science and*
1005 *Technology*, 25(2), 129-137.
- 1006 Takeshi, Y., & Okihiko, S. (1994). Stabilization of vitamin A. Shiseido
1007 Corporation Ltd., Japanese patent JP 6032774.
- 1008 Tesoriere, L., Darpa, D., Re, R., & Livrea, M. A. (1997). Antioxidant
1009 reactions of all-trans retinol in phospholipid bilayers: effect of oxygen

- 1010 partial pressure, radical fluxes, and retinol concentration. *Archives of*
1011 *Biochemistry and Biophysics*, 343(1), 13-18.
- 1012 Villamor, E., & Fawzi, W. W. (2005). Effects of Vitamin A
1013 supplementation on immune responses and correlation with clinical
1014 outcomes. *Clinical Microbiology Reviews*, 18(3), 446-464.
- 1015 Walker, S. A., Kennedy, M. T., & Zasadzinski, J. (1997).
1016 Encapsulation of bilayer vesicles by self-assembly. *Nature*, 387(1),
1017 61-64.
- 1018 Weiser, H., & Somorjai, G. (1992). Bioactivity of cis and dicis isomers
1019 of vitamin A esters. *International Journal for Vitamin and Nutrition*
1020 *Research*, 62(3), 201-208.
- 1021 Yaghmur, A., DeCampo, L., Sagalowicz, L., Leser, M., Glatter, O.,
1022 Michel, M., *et al.* (2007). Oil-in-water emulsion for delivery. Nestec
1023 S.A., US patent application 20070213234 A1.
- 1024 Yap, K. L., Liu, X., Thenmozhiyal, J. C., & Ho, P. C. (2005).
1025 Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion
1026 complexes by phase solubility, photostability, physicochemical and
1027 computational analysis. *European Journal of Pharmaceutical*
1028 *Sciences*, 25(1), 49-56.
- 1029 Ye, A., Flanagan, J., & Singh, H. (2006). Formation of stable nano-
1030 particles via electrostatic complexation between sodium caseinate
1031 and gum arabic. *Biopolymers*, 82(2), 121-133.

1032 Yoshida, K., Sekine, T., Matsuzaki, F., Yanaki, T., & Yamaguchi, M.
1033 (1999). Stability of vitamin A in oil-in-water-in-oil-type multiple
1034 emulsions. *Journal of the American Oil Chemists' Society*, 76(2),
1035 195-200.

1036 Young, A. M., & Gregoriadis, G. (1996). Photolysis of retinol in
1037 liposomes and its protection with tocopherol and oxybenzone.
1038 *Photochemistry and Photobiology*, 63(3), 344-352.

1039 Zarif, L. (2005). Drug delivery by lipid cochleates. *Methods in*
1040 *Enzymology*, 391, 314-329.

1041 Zarif, L., Jin, T., Segarra, I., & Mannino, R. (2005). Novel cochleate
1042 formulations. University of Medicine and Dentistry of New Jersey, US
1043 patent application 20050186265.

1044 Zsila, F., Bikadi, Z., & Simonyi, M. (2002). Retinoic acid binding
1045 properties of the lipocalin member beta-lactoglobulin studied by
1046 circular dichroism, electronic absorption spectroscopy and molecular
1047 modeling methods. *Biochemical Pharmacology*, 64(11), 1651-1660.

1048

1049


1050

1051 This work was funded by BASF, Germany and the NZ Foundation for
1052 Research, Science and Technology. The authors thank BioDelivery
1053 Sciences International Inc. for permission to reproduce figure 2.

1054

1055

1056




1057

1058

1059 **Fig. 1.** Structure of selected retinoids, where R is one of: A, retinol;

1060 B, retinoic acid; C, retinaldehyde; D, retinyl palmitate.



1061

1062 **Fig. 2.** Schematic representation of nanocochleate structure.

1063 Copyright BioDelivery Sciences International, Inc.

1064 **Table 1. Relative vitamin A activity of retinyl acetate isomers.**

RA ^a isomer	Relative vitamin A activity ^b	
	Ames <i>et al.</i> (1955)	Weiser and Somorjai (1992)
<i>all-trans</i>	100	100
<i>13-cis</i>	75	76
<i>11-cis</i>		31
<i>9-cis</i>	22	19
<i>7-cis</i>		18
<i>9,13-di-cis</i>	24	16
<i>11,13-di-cis</i>	23	18

1065

1066 ^aRA, retinyl acetate1067 ^bthe activity of the *all-trans* isomer is arbitrarily designated as 100%

1068

1069 **Table 2. Ability of various encapsulation systems to entrap and protect vitamin A.**

reference	technology	food safe?	AA ^a	loading capacity ^b % w/w	entrapment efficiency ^c %	stability improvement
Yoshida <i>et al.</i> (1999)	O/W/O emulsion	?	RO	0.47	83.5	after storage at 50°C for 4 weeks, 60% of retinol remained, while retinol in paraffin was completely degraded.
Jenning & Gohla (2001)	glyceryl behenate SLN	yes	RO	10 ^d	ND ^e	after storage at 40°C for 160 days, 60% of retinol remained, compared with 50% of retinol in an O/W emulsion
Carlotti <i>et al.</i> (2005)	cetyl palmitate SLN in cosmetic O/W emulsion	?	RP	9 ^d	ND	after UV irradiation for 120 min, 70% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion
	glyceryl behenate SLN in cosmetic O/W emulsion	?	RP	9 ^d	ND	after UV irradiation for 120 min, 51% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion
	palmitic acid SLN in cosmetic O/W emulsion	?	RP	5.6 ^d	ND	after UV irradiation for 120 min, 66% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion

Lee <i>et al.</i> (2002)	PC and soybean oil liposomes	no	RO	0.99	99.25 ± 0.47	after 8 days at 25°C, pH 7.0 without light, 50% of retinol in liposomes remained, while free retinol in buffer was completely degraded after 8 days at 25°C, pH 7.0 under UV light, 20% of retinol in liposomes remained, while free retinol in buffer was completely degraded
Munoz-Botella <i>et al.</i> (2002)	β-cyclodextrin complex	no	ATRA	0.13 ^d	ND	after exposure to light for 60 min, 44.3% of ATRA with β-CD remained in <i>all-trans</i> form, compared with 31.8% for ATRA in ethanol
	DM-β-cyclodextrin ^f complex	no	ATRA	0.11 ^d	ND	after exposure to light for 60 min, 54.6% of ATRA with DM-β-CD ^f remained in <i>all-trans</i> form, compared with 31.8% of ATRA in ethanol
Lin <i>et al.</i> (2000)	2-HP-β-cyclodextrin ^g complex	yes	ATRA	0.57 ^d	ND	after exposure to light at 40°C for 6 h, 22% of ATRA with HP-β-CD ^g remained, compared with 18% of ATRA in methanol
Lee <i>et al.</i> (2001)	silica microspheres	no	RO	2.23-2.82	35.9-44.0	not tested
Hwang <i>et al.</i> (2005)	silica microspheres	no	RO	not reported	7.4-30.9	not tested
Jeong <i>et al.</i> (2003)	polymer particles	no	ATRA	1.66-8.83	27.1-54.9	not tested
Duclairoir <i>et al.</i>	gliadin nanoparticles	yes	ATRA	7.64	75	not tested

(1999)

Shimoyamada <i>et al.</i> (1996)	β -lactoglobulin complex	yes	RO	1.3 ^{d,h}	ND	after 6 h under UV light, 92% of retinol remained, while 45% of free retinol remained.
Hattori <i>et al.</i> (1995)	β -lactoglobulin complex	yes	RO	0.7 ^{d,h}	ND	after holding at 50°C for 5 h, 80% of retinol with β -lactoglobulin remained, while 25% of retinol in buffer remained. after exposure to fluorescent light for 5 h, 36% of retinol with β -lactoglobulin remained, while 20% of retinol in buffer remained.

1071 ^aactive agent: RO, retinol; RP, retinyl palmitate; ATRA, all-*trans* retinoic acid

1072 ^b loading capacity = $\frac{\text{entrapped AA}}{\text{entrapped AA} + \text{matrix}} \times 100$

1073 ^c entrapment efficiency = $\frac{\text{total AA} - \text{unentrapped AA}}{\text{total AA}} \times 100$

1074 ^dnominal loading capacity, assuming 100% entrapment efficiency

1075 ^enot determined

1076 ^fDM- β -cyclodextrin, DM- β -CD: heptakis (2,6-O-dimethyl)-beta-cyclodextrin

1077 ^gHP- β -cyclodextrin, HP- β -CD: hydroxypropyl-beta-cyclodextrin

1078 ^hcalculated from concentrations of β -lactoglobulin and retinol using the molecular weight of β -lactoglobulin-A reported in Farrell *et al.*,
1079 2004

1080

1081